G-CSFR Inhibitors
2 drugsAbout G-CSFR
G-CSFR (Granulocyte Colony-Stimulating Factor Receptor) stimulates granulocyte production, a white blood cell type crucial for immune defense. As a key regulator of neutrophil production, it presents a valuable target for therapeutic intervention.
Currently, there is no genetic evidence directly linking G-CSFR to specific diseases. However, the existence of approved drugs targeting G-CSFR demonstrates its clinical relevance and therapeutic potential.
Two approved drugs, GRANIX and ROLVEDON, target G-CSFR, both of which are biologics. These drugs, developed by SICOR BIOTECH and SPECTRUM PHARMS respectively, highlight the feasibility of targeting this receptor.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Recurrent Chronic Myelomonocytic Leukemia with only 3 trials.
Top Drugs
The competitive landscape includes two companies, SICOR BIOTECH and SPECTRUM PHARMS, with approved drugs.
The limited number of players suggests relatively low barriers to entry, but also a potentially smaller market.
Drug Modality Landscape
Modalities
Routes of Administration
G-CSFR requires biologic approaches (biologic (other)), likely due to its structure or location.
The lack of small molecule or antibody drugs targeting G-CSFR represents a potential whitespace opportunity.
Clinical Trials 361 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 148 | 81 | 31 | 34 | 72% |
| Phase 2 | 154 | 84 | 25 | 45 | 77% |
| Phase 3 | 49 | 29 | 10 | 10 | 74% |
| Phase 4 | 10 | 5 | 3 | 2 | 63% |
Top Sponsors
By Modality
Top Conditions
Drug Approval Timeline (1991 - 2024)
The first drug was approved in 2012 (GRANIX), with the most recent approval in 2022 (ROLVEDON).
The 11-year span between approvals suggests a slow but steady interest in targeting G-CSFR.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 181 clinical trials targeting G-CSFR.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities